Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
One‐food elimination diet vs six‐food elimination diet Histological improvement at 6 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.85 [0.54, 1.33] | 1 study · 129 participants | Very low |
One‐food elimination diet vs six‐food elimination diet Histological improvement at 6 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 129 participants | Very low |
One‐food elimination diet vs six‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Endoscopic improvement at 6 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 129 participants | Very low |
Corticosteroids vs placebo Withdrawals due to adverse events (2 to 12 weeks) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.64 [0.43, 0.96] | 14 studies · 1032 participants | Low |
One‐food elimination diet vs six‐food elimination diet Withdrawals due to adverse events · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.62 [0.11, 3.57] | 1 study · 129 participants | Very low |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Histological improvement at 8 to 12 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.57 [0.99, 2.48] | 1 study · 64 participants | Very low |
Four‐food elimination diet with omeprazole vs omeprazole Histological improvement at 8 to 12 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 58 participants | Very low |
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Withdrawals due to adverse events at 8 to 12 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 5 [0.62, 40.44] | 1 study · 64 participants | Very low |
Four‐food elimination and amino acid formula vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Corticosteroids vs placebo Clinical improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2.17 [0.75, 6.27] | 2 studies · 252 participants | Very low |
Four‐food elimination and amino acid formula vs four‐food elimination diet Histological improvement at 6 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.9 [0.79, 4.6] | 1 study · 41 participants | Very low |
Four‐food elimination and amino acid formula vs four‐food elimination diet Histological improvement at 6 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Four‐food elimination and amino acid formula vs four‐food elimination diet Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Endoscopic improvement at study endpoint (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Four‐food elimination and amino acid formula vs four‐food elimination diet Withdrawals due to adverse events at 6 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.95 [0.06, 14.22] | 1 study · 41 participants | Very low |
Nebulized budesonide vs viscous budesonide Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Clinical improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Nebulized budesonide vs viscous budesonide Histological improvement at 8 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Histological improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Nebulized budesonide vs viscous budesonide Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Corticosteroids vs placebo Clinical improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 3 studies · 269 participants | Very low |
Nebulized budesonide vs viscous budesonide Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Withdrawals due to adverse events at 8 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Viaskin milk patch vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Clinical improvement at 44 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 9 participants | Low |
Viaskin milk patch vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Histological improvement at 44 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 9 participants | Low |
Viaskin milk patch vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Endoscopic improvement at 44 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 20 participants | Low |
Viaskin milk patch vs placebo Withdrawals due to adverse events at 44 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.12 [0.05, 23.99] | 1 study · 20 participants | Low |
Leukotriene receptor antagonist vs placebo Clinical improvement at 26 weeks (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.68 [0.66, 4.28] | 1 study · 41 participants | Very low |
Omeprazole vs placebo Improvement in symptoms in infants · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Esomeprazole vs placebo Adverse events ‐ not reported · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo pH indices ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo Endoscopic metrics ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) Improvement in symptoms · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 127 participants | Very low |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) Adverse events · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 127 participants | Very low |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) Improvement in endoscopic appearances · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 127 participants | Very low |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in symptoms · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Adverse events · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs placebo Adverse events ‐ not reported · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in endoscopic metrics ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |